Eckert & Ziegler: Re-Enter the U.S Market with Therapeutic Products
Eckert & Ziegler Strahlen- und Medizintechnik AG / Alliance
03.12.2009
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Berlin, December 3rd, 2009. -- The Radiation Therapy Division of Eckert & Ziegler (ISIN DE0005659700) is preparing its re-entry into the U.S. market. As the Belgian portfolio company IBt Bebig reported last night, it has entered into a strategic alliance with Core Oncology Inc. of Santa Barbara, California, USA. The agreement calls for covering initially the cross marketing of products of both companies and the definition of mutual R&D programs. As part of the agreement, IBt Bebig made a two million USD investment in Core Oncology. The investment has taken the form of a subordinated loan maturing before the end of 2010. Both groups are investigating the possibilities to collaborate further together. The board of Eckert & Ziegler expects already in 2010 stimuli from the close collaboration for further growth in revenues and profits of the Therapy segment. It is also expected that the Radiation Therapy Division, like the whole group, can at least double its revenues within the next five years while maintaining the profitability.
Information and Explaination of the Issuer to this News:
For further details see also the publication at www.ibt-bebig.eu
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.com
03.12.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service